Authors: Karp, JE Kaufmann, SH Adjei, AA Lancet, JE Wright, JJ End, DW

Citation: Je. Karp et al., Current status of clinical trials of farnesyltransferase inhibitors, CURR OPIN O, 13(6), 2001, pp. 470-476

Authors: End, DW Smets, G Todd, AV Applegate, TL Fuery, CJ Angibaud, P Venet, M Sanz, G Poignet, H Skrzat, S Devine, A Wouters, W Bowden, C

Citation: Dw. End et al., Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, CANCER RES, 61(1), 2001, pp. 131-137

Authors: Karp, JE Lancet, JE Kaufmann, SH End, DW Wright, JJ Bol, K Horak, I Tidwell, ML Liesveld, J Kottke, TJ Ange, D Buddharaju, L Gojo, I Highsmith, WE Belly, RT Hohl, RJ Rybak, ME Thibault, A Rosenblatt, J

Citation: Je. Karp et al., Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial, BLOOD, 97(11), 2001, pp. 3361-3369

Authors: Zujewski, J Horak, ID Bol, CJ Woestenborghs, R Bowden, C End, DW Piotrovsky, VK Chiao, J Belly, RT Todd, A Kopp, WC Kohler, DR Chow, C Noone, M Hakim, FT Larkin, G Gress, RE Nussenblatt, RB Kremer, AB Cowan, KH

Citation: J. Zujewski et al., Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer, J CL ONCOL, 18(4), 2000, pp. 927-941

Authors: End, DW

Citation: Dw. End, Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway, INV NEW DR, 17(3), 1999, pp. 241-258